Tag: MDC
Medlab Clinical’s NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study
Australian biotech Medlab Clinical (ASX: MDC) has reported the first cohort of patients undergoing a 12-month study of its NanaBis cannabinoid treatment for cancer-induced bone pain have registered a ...
Medlab Clinical to be granted European patent for NanoCelle drug delivery platform
Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a patent covering the use of the company’s NanoCelle drug d...
Medlab Clinical tops up cash reserves, builds board capabilities with new appointment
Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment of “leading” pharmaceutical executive Cheryl Maley.
...
Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1
Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue from Special Access Scheme (SAS) sales of its NanaBis an...
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-track availability of its proprietary cannabinoid formulat...
Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms
Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic has revealed a “significant” reduction in depression.
The trial involved administering NRGBiotic to ...
Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials
Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outperforms opioids for cancer-related pain management, should...
Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis
Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lead candidate NanaBis, which is designed for treating canc...
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that ...
Medlab’s NanaBis spray deemed safe for chronic pain management in patients with advanced breast and prostate cancers
Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel drug candidate to be safe, tolerable and fast-acting with...
Medlab trial shows Nanostat spray delivers improved metabolic functioning over tablet version
Australian-based Medlab Clinical (ASX: MDC) has reported results of a bioequivalence trial involving an orobuccal spray version of its Nanostat cardiovascular medication which have indicated improved ...
Export licence granted to Medlab in development of cannabis pain management products
Australian life sciences company Medlab Clinical (ASX: MDC) has been granted a licence to export cannabis relating to the development of its NanaBis and NanaBidial cancer pain management medications.
...
Medlab Clinical gets positive feedback from doctors prescribing cannabis for cancer pain
Medlab Clinical (ASX: MDC) has claimed it has received positive feedback from doctors prescribing its cannabis-based medicine NanaBis for the pain management of cancer patients.
The Australian medi...
